• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Oncology Device Market

    ID: MRFR/Pharma/32277-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Oncology Device Market Research Report By Application (Radiation Therapy, Chemotherapy, Surgical Oncology, Supportive Care, Diagnostic Imaging), By Device Type (Radiotherapy Equipment, Chemotherapy Administration Devices, Surgical Instruments, Diagnostic Imaging Devices, Supportive Devices), By End User (Hospitals, Ambulatory Surgical Centers, Specialized Oncology Clinics, Home Care Settings), By Technology (Photodynamic Therapy, Radiotherapy, Cryoablation, Electrochemotherapy) and By Regional (North America, Europe, South America, Asia Paci...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Oncology Device Market Infographic

    Oncology Device Market Summary

    As per MRFR analysis, the Oncology Device Market Size was estimated at 78.82 USD Billion in 2024. The Oncology Device industry is projected to grow from 83.69 USD Billion in 2025 to 152.48 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.18 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Oncology Device Market is experiencing robust growth driven by technological innovations and increasing healthcare demands.

    • Technological advancements in imaging are enhancing diagnostic accuracy and treatment planning in oncology.
    • The rise of minimally invasive procedures is transforming patient care and recovery times in cancer treatment.
    • Integration of artificial intelligence is streamlining workflows and improving patient outcomes in oncology devices.
    • Increasing cancer incidence and advancements in treatment technologies are driving demand, particularly in North America and the Asia-Pacific region.

    Market Size & Forecast

    2024 Market Size 78.82 (USD Billion)
    2035 Market Size 152.48 (USD Billion)
    CAGR (2025 - 2035) 6.18%

    Major Players

    Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Philips (NL), Bayer (DE), Varian Medical Systems (US), GE Healthcare (US), Stryker Corporation (US)

    Oncology Device Market Trends

    The Oncology Device Market is currently experiencing a transformative phase characterized by rapid advancements in technology and an increasing focus on personalized medicine. Innovations in imaging technologies, such as enhanced MRI and PET scans, are enabling more precise tumor detection and characterization. Furthermore, the integration of artificial intelligence in diagnostic tools is streamlining workflows and improving accuracy, which may lead to better patient outcomes. As healthcare systems worldwide prioritize early detection and treatment, the demand for sophisticated oncology devices is likely to rise, reflecting a shift towards more proactive healthcare strategies. In addition to technological advancements, the Oncology Device Market is witnessing a growing emphasis on minimally invasive procedures. These techniques, which often result in reduced recovery times and lower complication rates, are becoming increasingly popular among both healthcare providers and patients. The trend towards outpatient care is also influencing the market, as devices that facilitate such procedures gain traction. Overall, the Oncology Device Market appears poised for substantial growth, driven by innovation, patient-centric approaches, and a commitment to improving cancer care.

    Technological Advancements in Imaging

    Recent innovations in imaging technologies are revolutionizing the Oncology Device Market. Enhanced modalities, such as advanced MRI and PET scans, provide improved tumor visualization and characterization, facilitating earlier and more accurate diagnoses. This trend is likely to continue as research and development efforts focus on refining these technologies.

    Rise of Minimally Invasive Procedures

    The Oncology Device Market is increasingly leaning towards minimally invasive techniques, which offer numerous benefits, including shorter recovery times and reduced risk of complications. This shift is reshaping surgical practices and is likely to enhance patient satisfaction and outcomes.

    Integration of Artificial Intelligence

    The incorporation of artificial intelligence into oncology devices is transforming diagnostic processes. AI algorithms are being utilized to analyze imaging data, improving accuracy and efficiency in tumor detection. This trend suggests a future where AI plays a pivotal role in personalized cancer treatment.

    The Global Oncology Device Market is poised for transformative growth, driven by advancements in technology and an increasing emphasis on personalized medicine, which collectively enhance treatment efficacy and patient outcomes.

    U.S. Food and Drug Administration (FDA)

    Oncology Device Market Drivers

    Increasing Cancer Incidence

    The Oncology Device Market is experiencing growth due to the rising incidence of cancer worldwide. According to recent statistics, cancer cases are projected to increase significantly, with estimates suggesting that by 2040, the number of new cancer cases could reach 29.5 million annually. This alarming trend necessitates the development and deployment of advanced oncology devices to facilitate early detection, diagnosis, and treatment. As healthcare systems strive to manage this growing burden, investments in innovative oncology devices are likely to surge, driving market expansion. Furthermore, the increasing awareness of cancer screening and preventive measures among populations contributes to the demand for sophisticated oncology devices, thereby enhancing the overall market landscape.

    Advancements in Treatment Technologies

    The Oncology Device Market is propelled by continuous advancements in treatment technologies. Innovations such as targeted therapies, immunotherapies, and personalized medicine are reshaping the treatment landscape for cancer patients. The integration of these advanced treatment modalities with oncology devices enhances their efficacy and precision. For instance, the development of next-generation sequencing technologies has revolutionized the way oncologists approach cancer treatment, allowing for tailored therapies based on individual genetic profiles. This shift towards personalized treatment is expected to drive the demand for advanced oncology devices, as healthcare providers seek to optimize patient outcomes. As a result, the Oncology Device Market is likely to witness substantial growth, fueled by the need for devices that can support these cutting-edge treatment approaches.

    Regulatory Support for Innovative Devices

    The Oncology Device Market is experiencing favorable regulatory support, which is crucial for the introduction of innovative oncology devices. Regulatory bodies are increasingly streamlining approval processes for new devices, thereby encouraging manufacturers to invest in research and development. This supportive environment facilitates the rapid introduction of cutting-edge technologies that can significantly improve cancer diagnosis and treatment. For example, the expedited approval pathways for breakthrough devices allow for quicker access to life-saving technologies for patients. As regulatory frameworks continue to evolve, the Oncology Device Market is expected to expand, driven by the influx of innovative devices that meet the growing needs of healthcare providers and patients alike.

    Rising Demand for Home Healthcare Solutions

    The Oncology Device Market is witnessing a shift towards home healthcare solutions, driven by the increasing demand for patient-centered care. Patients are increasingly seeking options that allow them to manage their health from the comfort of their homes, particularly in the context of cancer treatment. This trend is prompting manufacturers to develop oncology devices that are suitable for home use, such as portable diagnostic tools and remote monitoring systems. The convenience and accessibility of these devices are appealing to patients and healthcare providers alike, as they facilitate ongoing care and monitoring without the need for frequent hospital visits. Consequently, the Oncology Device Market is likely to grow as more innovative home healthcare solutions are introduced, catering to the evolving preferences of patients.

    Growing Investment in Healthcare Infrastructure

    The Oncology Device Market is benefiting from increased investment in healthcare infrastructure across various regions. Governments and private entities are recognizing the importance of enhancing healthcare facilities to address the rising cancer burden. This investment is directed towards upgrading medical equipment, including oncology devices, to ensure that healthcare providers can deliver high-quality care. For instance, the establishment of specialized cancer treatment centers is on the rise, which necessitates the procurement of advanced oncology devices. Additionally, funding for research and development in oncology is expanding, leading to the introduction of innovative devices that improve diagnostic and therapeutic capabilities. This trend is likely to bolster the Oncology Device Market, as enhanced infrastructure supports the adoption of advanced technologies.

    Market Segment Insights

    By Application: Radiation Therapy (Largest) vs. Chemotherapy (Fastest-Growing)

    In the Oncology Device Market, Radiation Therapy emerges as the largest segment, widely adopted for its effectiveness in treating various types of cancers. It captures a significant share due to its established technology and integration in treatment protocols. Following closely is Chemotherapy, an essential part of cancer treatment that is increasingly being utilized alongside targeted therapies, expanding its market presence. The overall distribution of market share showcases a competitive landscape, with Surgical Oncology, Supportive Care, and Diagnostic Imaging also holding substantial positions as they cater to the holistic treatment of cancer patients.

    Radiation Therapy (Dominant) vs. Chemotherapy (Emerging)

    Radiation Therapy stands as the dominant player in the Oncology Device Market, characterized by a comprehensive range of technologies such as linear accelerators and brachytherapy systems. Its robust implementation across various healthcare settings underscores its pivotal role in the oncological treatment landscape. In contrast, Chemotherapy is marked as an emerging segment, rapidly evolving with advancements in drug formulations and personalized medicine approaches. This dynamic growth is driven by ongoing research, increasing approvals of new chemotherapeutic agents, and the integration of supportive therapies which enhance patient outcomes and therapy efficacy. These characteristics contribute to Chemotherapy's accelerated adoption and its potential to grow within the oncology framework.

    By Device Type: Radiotherapy Equipment (Largest) vs. Chemotherapy Administration Devices (Fastest-Growing)

    The Oncology Device Market showcases a diverse range of device types contributing to cancer treatment efficiency. Among these, Radiotherapy Equipment holds the largest market share, primarily due to the increasing adoption of advanced technologies and patient demand for effective cancer therapies. In contrast, Chemotherapy Administration Devices are rapidly gaining traction, reflecting a shift towards more efficient drug delivery systems and automated solutions in treatment protocols.

    Radiotherapy Equipment (Dominant) vs. Chemotherapy Administration Devices (Emerging)

    Radiotherapy Equipment represents the cornerstone of cancer treatment, encompassing technologies such as linear accelerators and brachytherapy systems. As the dominant segment, it benefits from continuous innovations and upgrades that enhance treatment precision and patient outcomes. On the other hand, Chemotherapy Administration Devices are emerging as vital tools that improve the efficiency of drug delivery and minimize patient discomfort. These devices often include infusion pumps and portable delivery systems designed to support outpatient therapies, significantly transforming traditional chemotherapy practices and enhancing the overall treatment experience.

    By End User: Hospitals (Largest) vs. Specialized Oncology Clinics (Fastest-Growing)

    In the Oncology Device Market, the distribution of market share among end users reveals a dominant position held by hospitals, which cater to a significant portion of oncology patients, offering a comprehensive range of treatment services and advanced technologies. Ambulatory surgical centers and specialized oncology clinics also contribute to this segment, although to a lesser extent. Home care settings are gradually emerging, providing convenience but still lagging compared to larger institutions. The growth trends within this segment highlight a shift towards specialized treatment facilities, with specialized oncology clinics showing the fastest growth rate. This trend is driven by the increasing focus on personalized medicine and the demand for advanced cancer therapies. Furthermore, the move towards decentralized care has enhanced the role of home care settings, leading to a diversified approach in patient management.

    Hospitals (Dominant) vs. Specialized Oncology Clinics (Emerging)

    Hospitals represent the dominant end-user segment in the Oncology Device Market due to their extensive resources, multidisciplinary teams, and capability to offer comprehensive cancer care. They are equipped with advanced imaging and treatment technologies, making them a primary choice for complex oncology cases. Conversely, specialized oncology clinics are emerging rapidly, driven by the rising demand for specialized care, patient-centric approaches, and streamlined services that cater specifically to cancer treatment. These clinics often provide targeted therapies and clinical trials, appealing to patients seeking cutting-edge treatment options. While hospitals remain prevalent, the specialized clinics are carving out a significant niche, offering alternatives that are increasingly sought after by patients.

    By Technology: Radiotherapy (Largest) vs. Electrochemotherapy (Fastest-Growing)

    In the Oncology Device Market, Radiotherapy remains the largest segment, capturing a significant share due to its established efficacy in treating various cancers. It is widely adopted across healthcare facilities and is supported by extensive clinical data. Following Radiotherapy, Photodynamic Therapy and Cryoablation hold notable shares, providing effective targeted treatment options. Electrochemotherapy, while smaller in share, is gaining attention for its innovative approach. The market is witnessing a shift towards these technologies due to their therapeutic advantages and patient-centric benefits.

    Technology: Radiotherapy (Dominant) vs. Electrochemotherapy (Emerging)

    Radiotherapy stands as the dominant technology in the Oncology Device Market, leveraging advanced imaging and treatment techniques to precisely target tumors while minimizing damage to surrounding tissues. Its widespread application in clinical settings, combined with ongoing advancements such as stereotactic body radiotherapy, reinforces its market leadership. In contrast, Electrochemotherapy is emerging as a promising treatment modality, harnessing the synergy of chemotherapy and electrical pulses to enhance drug delivery within tumor cells. This innovative approach is particularly appealing for patients with inaccessible tumors and is being increasingly integrated into clinical practice, signalling a shift towards less invasive cancer treatment methods.

    Get more detailed insights about Oncology Device Market

    Regional Insights

    North America : Leading Innovation and Demand

    North America is the largest market for oncology devices, holding approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing cancer prevalence, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes innovation, ensuring rapid approval of new technologies. The demand for minimally invasive procedures and personalized medicine is also on the rise, contributing to market expansion. The United States is the primary contributor to this market, with key players such as Medtronic, Boston Scientific, and Abbott Laboratories leading the charge. The competitive landscape is characterized by continuous innovation and strategic partnerships among major companies. Canada also plays a significant role, focusing on enhancing healthcare access and improving patient outcomes. The presence of established firms and emerging startups fosters a dynamic environment for growth.

    Europe : Regulatory Support and Growth

    Europe is the second-largest market for oncology devices, accounting for approximately 30% of the global share. The region benefits from robust healthcare systems and a growing aging population, which drives demand for cancer treatment technologies. Regulatory frameworks, such as the Medical Device Regulation (MDR), ensure high safety and efficacy standards, fostering consumer confidence and market growth. Additionally, increasing investments in healthcare technology and research are expected to propel the market further. Germany, France, and the UK are the leading countries in this market, with significant contributions from companies like Siemens Healthineers and Philips. The competitive landscape is marked by a mix of established players and innovative startups, focusing on advanced technologies such as AI and robotics in oncology. Collaborative efforts between public and private sectors are enhancing research capabilities and accelerating product development, positioning Europe as a key player in the oncology device market.

    Asia-Pacific : Rapid Growth and Potential

    Asia-Pacific is witnessing rapid growth in the oncology device market, holding approximately 20% of the global share. The region's expansion is fueled by increasing cancer incidence, rising healthcare expenditure, and a growing focus on advanced medical technologies. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to enhance access to oncology devices. Regulatory bodies are also streamlining approval processes to encourage innovation and market entry. China is the largest market in the region, followed by Japan and India, with a strong presence of both local and international players. Companies like GE Healthcare and Varian Medical Systems are actively expanding their operations in this region. The competitive landscape is characterized by a mix of established firms and emerging startups, focusing on affordable and effective oncology solutions. The increasing collaboration between governments and private sectors is expected to further boost market growth.

    Middle East and Africa : Emerging Market with Challenges

    The Middle East and Africa region is gradually emerging in the oncology device market, holding about 5% of the global share. The growth is driven by increasing cancer awareness, improving healthcare infrastructure, and rising investments in medical technology. However, challenges such as economic disparities and regulatory hurdles remain. Countries like South Africa and the UAE are leading the market, with efforts to enhance healthcare access and treatment options for cancer patients. South Africa is the largest market in the region, supported by a growing number of healthcare facilities and initiatives aimed at improving cancer care. The competitive landscape includes both local manufacturers and international companies looking to expand their footprint. Key players are focusing on partnerships and collaborations to address the unique challenges of the region, aiming to provide innovative and cost-effective oncology solutions.

    Key Players and Competitive Insights

    The Oncology Device Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cancer, and a growing emphasis on personalized medicine. Major players such as Medtronic (US), Siemens Healthineers (DE), and Varian Medical Systems (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Medtronic (US) focuses on integrating digital health solutions into its oncology devices, while Siemens Healthineers (DE) emphasizes advanced imaging technologies to improve diagnostic accuracy. Varian Medical Systems (US) is dedicated to developing cutting-edge radiation therapy solutions, which collectively shape a competitive environment that prioritizes technological superiority and patient-centric approaches.

    Key business tactics within the Oncology Device Market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting substantial influence. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation. The collective strategies of these companies not only enhance their individual market positions but also contribute to a robust competitive framework that encourages continuous improvement and adaptation.

    In August 2025, Medtronic (US) announced a strategic partnership with a leading telehealth provider to enhance remote patient monitoring capabilities for oncology patients. This collaboration is significant as it aligns with the growing trend towards digital health solutions, enabling better patient engagement and potentially improving treatment outcomes. By integrating telehealth into its oncology device offerings, Medtronic (US) positions itself at the forefront of a rapidly evolving healthcare landscape.

    In September 2025, Siemens Healthineers (DE) launched a new AI-driven imaging platform designed to streamline the diagnostic process for oncologists. This innovation is crucial as it not only enhances the accuracy of cancer detection but also reduces the time required for diagnosis, thereby improving patient care. Siemens Healthineers (DE) appears to be capitalizing on the increasing demand for AI integration in healthcare, which may provide a competitive edge in the oncology device market.

    In July 2025, Varian Medical Systems (US) expanded its global footprint by establishing a new manufacturing facility in Asia, aimed at increasing production capacity for its advanced radiation therapy systems. This move is indicative of Varian's commitment to meeting the rising demand for oncology devices in emerging markets. By localizing production, Varian (US) not only reduces supply chain complexities but also enhances its ability to respond swiftly to regional market needs.

    As of October 2025, current competitive trends in the Oncology Device Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and deliver high-quality, reliable oncology solutions.

    Key Companies in the Oncology Device Market market include

    Industry Developments

    • Q2 2024: Varian Receives FDA Clearance for TrueBeam and Edge Radiotherapy Systems with HyperSight Imaging Varian, a Siemens Healthineers company, announced it received FDA 510(k) clearance for its TrueBeam and Edge radiotherapy systems equipped with HyperSight imaging, enhancing image-guided cancer treatment capabilities.
    • Q2 2024: RefleXion Announces FDA Clearance for SCINTIX Biology-Guided Radiotherapy for Lung and Bone Cancers RefleXion Medical received FDA clearance for its SCINTIX biology-guided radiotherapy to treat lung and bone cancers, expanding the clinical indications for its novel oncology device.
    • Q2 2024: OncoRes Medical Raises $17.5 Million in Series B Funding to Advance Intraoperative Imaging Device OncoRes Medical secured $17.5 million in Series B funding to accelerate the development and commercialization of its intraoperative imaging device for cancer surgery.
    • Q2 2024: Accuray Announces CE Mark for Radixact System with Synchrony for Real-Time Motion Synchronization Accuray received CE Mark approval for its Radixact System with Synchrony, enabling real-time motion synchronization during radiotherapy for cancer patients in Europe.
    • Q2 2024: Theragenics Corporation Acquires C4 Imaging to Expand Brachytherapy Portfolio Theragenics Corporation announced the acquisition of C4 Imaging, a developer of MRI markers for brachytherapy, to strengthen its position in the oncology device market.
    • Q3 2024: ViewRay Announces Partnership with Elekta to Integrate MRIdian MRI-Guided Radiation Therapy with Elekta’s Oncology Solutions ViewRay and Elekta entered a strategic partnership to integrate ViewRay’s MRIdian MRI-guided radiation therapy system with Elekta’s oncology workflow solutions.
    • Q3 2024: XACT Robotics Receives FDA Clearance for XACT ACE Robotic System for Percutaneous Procedures in Oncology XACT Robotics received FDA clearance for its XACT ACE Robotic System, enabling precise percutaneous procedures for oncology applications.
    • Q3 2024: Boston Scientific Announces FDA Approval of TheraSphere Y-90 Glass Microspheres for Colorectal Cancer Liver Metastases Boston Scientific received FDA approval for its TheraSphere Y-90 Glass Microspheres for the treatment of colorectal cancer liver metastases, expanding its interventional oncology portfolio.
    • Q4 2024: Nano-X Imaging Ltd. Announces FDA Clearance for Nanox.ARC Multi-Source Digital X-ray Device for Oncology Applications Nano-X Imaging Ltd. received FDA clearance for its Nanox.ARC multi-source digital X-ray device, which is designed to improve imaging for oncology diagnostics.
    • Q4 2024: Elekta Opens New Global Innovation Center for Radiation Therapy in Stockholm Elekta inaugurated a new global innovation center in Stockholm dedicated to advancing radiation therapy technologies for cancer treatment.
    • Q1 2025: CureMetrix Raises $30 Million Series C to Accelerate AI-Powered Oncology Imaging Solutions CureMetrix closed a $30 million Series C funding round to expand its AI-powered imaging solutions for oncology diagnostics and workflow optimization.
    • Q2 2025: Medtronic Announces FDA Approval of Hugo™ Robotic-Assisted Surgery System for Urologic Oncology Procedures Medtronic received FDA approval for its Hugo™ robotic-assisted surgery system, enabling its use in urologic oncology procedures in the United States.

    Future Outlook

    Oncology Device Market Future Outlook

    The Oncology Device Market is projected to grow at a 6.18% CAGR from 2024 to 2035, driven by technological advancements, increasing cancer prevalence, and rising healthcare expenditures.

    New opportunities lie in:

    • Development of AI-driven diagnostic imaging devices
    • Expansion of minimally invasive surgical tools
    • Integration of telehealth solutions for remote patient monitoring

    By 2035, the Oncology Device Market is expected to achieve substantial growth and innovation.

    Market Segmentation

    Oncology Device Market End User Outlook

    • Hospitals
    • Ambulatory Surgical Centers
    • Specialized Oncology Clinics
    • Home Care Settings

    Oncology Device Market Technology Outlook

    • Photodynamic Therapy
    • Radiotherapy
    • Cryoablation
    • Electrochemotherapy

    Oncology Device Market Application Outlook

    • Radiation Therapy
    • Chemotherapy
    • Surgical Oncology
    • Supportive Care
    • Diagnostic Imaging

    Oncology Device Market Device Type Outlook

    • Radiotherapy Equipment
    • Chemotherapy Administration Devices
    • Surgical Instruments
    • Diagnostic Imaging Devices
    • Supportive Devices

    Report Scope

    MARKET SIZE 202478.82(USD Billion)
    MARKET SIZE 202583.69(USD Billion)
    MARKET SIZE 2035152.48(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)6.18% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesIntegration of artificial intelligence in diagnostic imaging enhances precision in the Oncology Device Market.
    Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the Oncology Device Market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Leave a Comment

    FAQs

    What is the projected market valuation of the Oncology Device Market by 2035?

    The Oncology Device Market is projected to reach a valuation of 152.48 USD Billion by 2035.

    What was the market valuation of the Oncology Device Market in 2024?

    In 2024, the Oncology Device Market was valued at 78.82 USD Billion.

    What is the expected CAGR for the Oncology Device Market during the forecast period 2025 - 2035?

    The expected CAGR for the Oncology Device Market during the forecast period 2025 - 2035 is 6.18%.

    Which segment of the Oncology Device Market had the highest valuation in 2024?

    In 2024, the Chemotherapy segment had the highest valuation at 20.0 USD Billion.

    What are the key players in the Oncology Device Market?

    Key players in the Oncology Device Market include Medtronic, Boston Scientific, Abbott Laboratories, Siemens Healthineers, and Philips.

    What is the projected valuation for the Radiation Therapy segment by 2035?

    The Radiation Therapy segment is projected to reach a valuation of 30.0 USD Billion by 2035.

    How does the Surgical Oncology segment's valuation compare to the Supportive Care segment in 2024?

    In 2024, the Surgical Oncology segment was valued at 18.0 USD Billion, whereas the Supportive Care segment was valued at 12.06 USD Billion.

    What is the expected growth for Diagnostic Imaging Devices from 2024 to 2035?

    The Diagnostic Imaging Devices segment is expected to grow from 20.0 USD Billion in 2024 to 40.0 USD Billion by 2035.

    Which end user segment is projected to have the highest valuation by 2035?

    By 2035, the Hospitals segment is projected to have the highest valuation at 61.0 USD Billion.

    What is the projected growth for Chemotherapy Administration Devices from 2024 to 2035?

    Chemotherapy Administration Devices are projected to grow from 15.0 USD Billion in 2024 to 30.0 USD Billion by 2035.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions